Journal for ImmunoTherapy of Cancer

The Journal for ImmunoTherapy of CancerĀ (JITC) is an open access, peer-reviewed journal that aims to enrich communication and advance scientific understanding in the rapidly evolving fields of tumor immunology and cancer immunotherapy. Topics of interest range across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity.

Publisher
BMJ
Website
https://jitc.bmj.com/

Some content from Wikipedia, licensed under CC BY-SA

Oncology & Cancer

Antibiotics reveal a new way to fight cancer

Cancer cells grow and spread by hiding from the body's immune system. Immunotherapy allows the immune system to find and attack hidden cancer cells, helping cancer patients live longer lives. However, many patients get little ...

Medications

New cell-based immunotherapy offered for melanoma

Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, is one of the first centers nationwide to offer a newly approved cell-based immunotherapy that targets melanoma.